| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Angeloylgomisin O exhibits anti-inflammatory activity. It has been identified as a SARS-CoV-2 entry inhibitor that acts by blocking membrane fusion mediated by the viral spike (S) protein. The compound also exhibits antioxidant and hepatoprotective effects, protecting liver cells from oxidative and chemical stress. As a lignan compound, it may interact with various cellular targets involved in inflammation, oxidative stress, and viral entry. Its multiple biological activities make it a compound of interest for research on inflammation, liver protection, and antiviral strategies.
|
|---|---|
| ln Vitro |
In vitro studies have characterized Angeloylgomisin O as a lignan compound with anti-inflammatory properties. The compound exhibits potent antioxidant, anti-inflammatory, and hepatoprotective effects, protecting liver cells from oxidative and chemical stress. It has been identified as a SARS-CoV-2 entry inhibitor that blocks membrane fusion mediated by the viral spike protein. Its anti-inflammatory activity has been confirmed in various in vitro models. The compound's ability to protect liver cells from damage supports its hepatoprotective potential. Its antiviral activity against SARS-CoV-2 entry has been demonstrated in appropriate in vitro assays.
|
| ln Vivo |
In vivo studies of Angeloylgomisin O are not extensively reported in the available literature. As a lignan compound with anti-inflammatory and hepatoprotective effects, it would be expected to have activity in animal models of inflammation and liver injury. The compound's antioxidant properties suggest potential benefits in oxidative stress-related conditions. However, specific in vivo efficacy data are not extensively available. The compound is a natural product used for research purposes. Further studies would be required to fully characterize its in vivo activity.
|
| Enzyme Assay |
The in vitro assay for Angeloylgomisin O depends on the biological activity being measured. For anti-inflammatory activity, cells are treated with the compound and stimulated with inflammatory mediators such as LPS or cytokines; inflammatory markers such as cytokines, nitric oxide, or NF-kappaB activation are measured. For hepatoprotective activity, liver cells are treated with the compound and exposed to oxidative or chemical stress; cell viability and markers of liver damage are assessed. For antiviral activity, SARS-CoV-2 entry assays are performed using pseudovirus or live virus. IC50 or EC50 values are determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for Angeloylgomisin O are conducted using various cell lines depending on the activity being studied. For anti-inflammatory studies, macrophages or other immune cells are treated with the compound and stimulated with LPS; inflammatory cytokine production is measured by ELISA or qPCR. For hepatoprotective studies, hepatocytes or liver cell lines are treated with the compound and exposed to toxins; cell viability is assessed using MTT or LDH release assays. For antiviral studies, cells expressing ACE2 and TMPRSS2 are used to assess inhibition of SARS-CoV-2 spike-mediated entry. All experiments include appropriate controls.
|
| Animal Protocol |
In vivo animal studies for Angeloylgomisin O are not extensively reported. As a lignan compound with anti-inflammatory and hepatoprotective properties, it could be evaluated in animal models of inflammation, liver injury, or viral infection. Typical models include chemically induced liver injury, carrageenan-induced paw edema, or SARS-CoV-2 infection models. However, specific published studies are not available in the provided sources. The compound is a natural product for research purposes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Angeloylgomisin O are not extensively reported. The compound has a molecular weight of 498.56 g/mol and a molecular formula of C28H34O8. As a lignan compound, its pharmacokinetic properties would be influenced by its lipophilicity and molecular size. Specific parameters such as bioavailability, half-life, and tissue distribution are not readily available. The compound is a natural product for research purposes. For in vitro studies, it is typically dissolved in suitable solvents.
|
| Toxicity/Toxicokinetics |
Toxicology data for Angeloylgomisin O are not extensively reported. As a natural product-derived compound, it is expected to have a favorable safety profile, though this has not been systematically evaluated. The compound has been studied for its hepatoprotective effects, suggesting it may be well-tolerated. However, specific toxicity data, including LD50 values and organ toxicity profiles, are not available. The compound is for research use only and is not approved for therapeutic applications.
|
| References | |
| Additional Infomation |
It has been reported that Schisandra chinensis contains angelicin O, and relevant data is available.
See also: Schisandra chinensis fruit (partial). Angeloylgomisin O is a lignan compound extracted from Schisandra rubriflora (Schisandra chinensis) with anti-inflammatory properties. It has a molecular formula of C28H34O8 and a molecular weight of 498.56 g/mol. The compound exhibits antioxidant, anti-inflammatory, and hepatoprotective effects and has been identified as a SARS-CoV-2 entry inhibitor that blocks membrane fusion mediated by the viral spike protein. Angeloylgomisin O is a natural product used for research on inflammation, liver protection, and antiviral strategies. |
| Molecular Formula |
C28H34O8
|
|---|---|
| Molecular Weight |
498.565
|
| Exact Mass |
498.225
|
| CAS # |
83864-69-1
|
| PubChem CID |
91864462
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
608.3±55.0 °C at 760 mmHg
|
| Flash Point |
257.4±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.575
|
| LogP |
7.27
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
36
|
| Complexity |
786
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C/C=C(/C)\C(=O)O[C@@H]1[C@H]([C@H](CC2=CC3=C(C(=C2C4=C(C(=C(C=C14)OC)OC)OC)OC)OCO3)C)C
|
| InChi Key |
PLKFSXFJGNZAER-XXDSNBTQSA-N
|
| InChi Code |
InChI=1S/C28H34O8/c1-9-14(2)28(29)36-23-16(4)15(3)10-17-11-20-25(35-13-34-20)26(32-7)21(17)22-18(23)12-19(30-5)24(31-6)27(22)33-8/h9,11-12,15-16,23H,10,13H2,1-8H3/b14-9-/t15-,16-,23+/m0/s1
|
| Chemical Name |
[(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (Z)-2-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~200.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0057 mL | 10.0287 mL | 20.0574 mL | |
| 5 mM | 0.4011 mL | 2.0057 mL | 4.0115 mL | |
| 10 mM | 0.2006 mL | 1.0029 mL | 2.0057 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
